AI Generated Content

This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.

Tata Memorial Study Finds Ultra-Low Dose Immunotherapy Improves Survival, Cuts Cancer Treatment Costs

SUMMARY

AI Generated Content
  • Low-dose nivolumab improves survival, quality of life for relapsed cancer.
  • Ultra-low dose immunotherapy cuts costs by up to 90%.
  • Study shows no loss of effectiveness with lower nivolumab dose.
AD
Other Interesting Stories
AD